Literature DB >> 8708698

Possible distinct pathogenesis in low responder myasthenia gravis: association of soluble interleukin-2 receptor with acetylcholine receptor antibody titre or abnormal thymus.

M Hayashi, K Kida, J Yoshinaga.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8708698      PMCID: PMC1074004          DOI: 10.1136/jnnp.61.2.207

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  6 in total

1.  Follow-up of soluble interleukin-2 receptor levels after thymectomy in patients with myasthenia gravis.

Authors:  S Cohen-Kaminsky; Y Jacques; C Aime; D Safar; E Morel; S Berrih-Aknin
Journal:  Clin Immunol Immunopathol       Date:  1992-02

2.  Soluble interleukin-2 receptor in childhood non-Hodgkin's lymphoma.

Authors:  D M Komp; E Shapiro; J McNamara
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

3.  Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians.

Authors:  H C Chiu; A Vincent; J Newsom-Davis; K H Hsieh; T Hung
Journal:  Neurology       Date:  1987-12       Impact factor: 9.910

4.  Heterogeneity in myasthenia gravis: HLA phenotypes and autoantibody responses in ocular and generalized types.

Authors:  K Kida; M Hayashi; I Yamada; H Matsuda; J Yoshinaga; S Takami; S Yashiki; S Sonoda
Journal:  Ann Neurol       Date:  1987-03       Impact factor: 10.422

5.  Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.

Authors:  S Mossman; A Vincent; J Newsom-Davis
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

6.  Immune activation in myasthenia gravis: soluble interleukin-2 receptor, interferon-gamma and tumor necrosis factor-alpha levels in patients' serum.

Authors:  P Confalonieri; C Antozzi; F Cornelio; O Simoncini; R Mantegazza
Journal:  J Neuroimmunol       Date:  1993-10       Impact factor: 3.478

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.